Stock JAZZ PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Jazz Pharmaceuticals, Inc. Nasdaq

Equities

US4721471070

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Jazz Pharmaceuticals, Inc.
10/07 Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer CI
09/07 RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Jazz Pharmaceuticals Hosts Discussion of Healthcare Inequities in the U.S. To Honor Juneteenth
AQ
Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer
CI
RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating
MT
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
PR
Jazz Pharmaceuticals Publishes 2023 Corporate Sustainability and Social Impact Report: Progress, Responsibility and Innovation
AQ
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 3000E Growth Index
CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 1000 Growth Index
CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell Midcap Growth Index
CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 3000 Growth Index
CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell Small Cap Comp Growth Index
CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index
CI
Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday
MT
Sector Update: Health Care
MT
Jazz Pharmaceuticals Says Phase 2b Trial for Suvecaltamide Misses Primary Endpoint -- Shares Slump Pre-Bell
MT
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
RE
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
PR
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor
CI
Jazz Pharmaceuticals : 2023 Annual Report
PU
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. Stock
  5. News Jazz Pharmaceuticals, Inc.